Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (2): 325-330.doi: 10.3969/j.issn.1673-8225.2012.02.031

Previous Articles     Next Articles

R318A systematic review of proton therapy for non-small cell lung cancer 

Wang Xiao-jing1, 2, Tian Jin-hui1, Jiang Jin1, 2   

  1. 1Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou  730000, Gansu Province, China; 2Second Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China
  • Received:2011-04-23 Revised:2011-05-07 Online:2012-01-08 Published:2012-01-08
  • Contact: Tian Jin-hui, Master, Lecturer, Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China tjh996@163.com
  • About author:Wang Xiao-jing, Evidence Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, Gansu Province, China; Second Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu Province, China wang.xiaojing1990@163.com
  • Supported by:

    Science and Technology Innovation Team Construction Plan Regarding Heavy Ion Beam Irradiation for Treatment of Tumor, No. 098TTCA009*; Evidence Based Medical Innovation Program of Evidence Based Center of Lanzhou University, No. 2011LDEBM-B* 
       

PDF

515

Abstract:

BACKGROUND: The morbidity and mortality of non-small cell lung cancer (NSCLC) rank first in all countries worldwide, and radiotherapy is the main treatment for medically inoperable patients. This effect of proton energy deposition toward the end of the beam path is known as the Bragg peak. Accordingly, proton therapy should help improve the local control rate and minimize the incidence and severity of pulmonary, heart, and esophageal injury. However, the present role of proton therapy in the treatment lung cancer is still unclear.
OBJECTIVE: To assess the efficacy of the proton therapy for the NSCLC.
METHODS: We searched the electronic bibliographic databases, including Cochrane library, PubMed, EMBASE, China Journal Full-text Database, Chinese Biomedical Database, and Chinese Scientific Journals Full-text Database to assemble the clinical trials of the proton treatment for the NSCLC. Using the MINORS to evaluate the quality of studies, all the related date that matched our standards were abstracted for Meta analysis by RevMan 5.0.
RESULTS AND CONCLUSION: Eleven clinical trials including 308 patients, mainly stageⅠ were identified. No phase Ⅲ trials were found. 2-5 year local tumor control rates varied between 87% and 57%. The 2-year and 5-year overall survival varied 62%-84% and 29%. Late side effects were observed in about 10% of the patients. Compared with the photon therapy, proton treatment significantly reduced dose to the normal lung, esophagus, and spinal cord. Although current results with proton therapy for NSCLC are promising, more evidence is required before proton therapy can become internationally the standard treatment for lung cancer patients.

CLC Number: